Biogen. has been granted a patent for anti-VLA-4 antibodies and their binding fragments, including methods for treating multiple sclerosis and epilepsy. The patent also covers polynucleotides encoding these antibodies and specific sequences for their variable and constant regions. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of June 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.